VAXCYTE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 74.57 USD | -1.17% |
|
+14.39% | +18.74% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 8.11B |
|---|---|---|---|---|---|
| Net income 2024 * | -452M | Net income 2025 * | -507M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-18.6
x | P/E ratio 2025 * |
-17.2
x | Employees | 254 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vaxcyte, Inc.
More recommendations
More press releases
More news
| 1 day | -1.17% | ||
| 1 week | +14.39% | ||
| Current month | +23.15% | ||
| 1 month | +23.01% | ||
| 3 months | -0.92% | ||
| 6 months | +44.91% | ||
| Current year | +18.74% |
1 week
64.76
75.83
1 month
58.1075.83
Current year
53.8382.04
1 year
44.2082.04
3 years
16.7882.04
5 years
15.5182.04
10 years
15.5182.04
| Managers | Title | Age | Since |
|---|---|---|---|
Jeff Fairman
FOU | Founder | 60 | 13-05-26 |
Grant Pickering
FOU | Founder | 56 | 13-05-26 |
| Director of Finance/CFO | 55 | 20-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Grant Pickering
FOU | Founder | 56 | 13-05-26 |
Anne Drapeau
BRD | Director/Board Member | 57 | 21-09-15 |
Heath Lukatch
BRD | Director/Board Member | 56 | 18-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.27% | 0 M€ | 0.00% | - | |
| 0.10% | 0 M€ | 0.00% | - | |
| 0.08% | 1,487 M€ | +9.17% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 74.57 | -1.17% | 688,017 |
| 24-05-16 | 75.45 | +5.33% | 1,140,727 |
| 24-05-15 | 71.63 | +6.39% | 689,074 |
| 24-05-14 | 67.33 | +2.48% | 321,300 |
| 24-05-13 | 65.7 | +0.78% | 491,979 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Calendar
2024-06-05
- Jefferies Global Healthcare Conference
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
74.57
USD
Average target price
103.1
USD
Spread / Average Target
+38.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.74% | 8.11B | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- PCVX Stock
